As reported on PharmaBiz, Roche has secured CE mark approval for its Elecsys Neurofilament Light Chain (NfL) assay, a blood-based test designed to help detect neuroinflammation in adults with relapsing-remitting multiple sclerosis (RRMS). The authorization represents an important advance in multiple sclerosis care by offering clinicians a less invasive tool to track disease-related nerve damage over time.
Multiple sclerosis affects an estimated 2.9 million people globally and is characterized by inflammation and damage to the central nervous system. Ongoing assessment of disease activity is essential for optimizing treatment decisions, yet routine monitoring often relies on MRI scans, which can be costly, resource-intensive, and difficult for some patients to access regularly. Roche’s newly approved test aims to complement existing tools by providing biological insight through a blood draw.
The Elecsys NfL assay measures levels of neurofilament light chain, a structural protein found predominantly in neurons. When nerve fibers are damaged, NfL is released into cerebrospinal fluid and blood, making it a sensitive marker of neuroaxonal injury. Elevated NfL concentrations have been associated with a range of neurological conditions, including both acute and chronic disorders. In the context of RRMS, NfL levels can reflect underlying neuroinflammatory activity, supporting earlier detection of disease changes.
According to Roche, the test is intended to be used alongside clinical evaluation and imaging, rather than as a replacement. By adding a standardized biomarker to routine care, clinicians may be better equipped to reassess patients in a timely manner and tailor treatment strategies more precisely.
A key advantage of the Elecsys NfL test is its accessibility. The assay runs on Roche’s widely deployed cobas laboratory platforms, enabling consistent and comparable results across testing sites. Because it requires only a simple blood sample, collection can be performed locally, which could reduce the need for patients to travel to specialized centers and make more frequent monitoring feasible for a broader patient population.
The test previously received Breakthrough Device Designation from the US Food and Drug Administration in November 2023, highlighting its potential clinical value. With CE mark approval now in place, the assay can be made available in regions that recognize the CE designation, leveraging existing laboratory infrastructure for rapid adoption.
Neurology remains a major area of investment for Roche, spanning both diagnostics and therapeutics. The company is developing a broad portfolio of tools and medicines targeting conditions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and other serious neurological disorders. Through integrated diagnostic and treatment strategies, Roche aims to improve detection, monitoring, and long-term management of complex neurological diseases.
